Science Collected

🔥Module 2 is available! Continue our series of interactive e-learning modules that guide you in the diagnosis and management of #CKD patients. 🎯Module 2 focuses on the critical steps of diagnosing and initiating treatment of CKD. Start Module 2👉 bit.ly/41kDZAk

Gain valuable knowledge on managing #hyperkalaemia in cardiorenal patients. Watch the recorded symposium here 👉bit.ly/47nWZ2G #CardiorenalDisease #CKD #MedicalEducation

🎙️2 podcasts, 1 goal: Answers in 6 minutes. 3 critical steps in 3 months to save #CKD lives. How? eGFR dip and #SGLT2 inhibitors — any concern? Explore 2 podcasts with Prof. David Cherney & @kieranmccaffs on kidney care & SGLT2 inhibitors. 🎧Listen 👉 bit.ly/3QBkChy

📊 Explore our insightful infographic on SGLT2 inhibitors' role in #hypertension, #CKD, #HF & #T2D management based on the latest #ESH2023 guidelines. 🔗 Attached here 👉 bit.ly/3ugURLV

🔥Module 1 is out! Our 3 interactive e-learning modules guide you through the steps from the diagnosis and management of the #CKD patients. 🎯 Module 1 covers the steps to take for screening a patient with a risk of CKD. Start now 👉 bit.ly/3NqAy5x #MedEd

🔥Exciting news! Our expert-led educational presentations are now available! 📚Visualise your learning with engaging visuals and key points. 🔎Discover a goldmine of knowledge in #renal , #cardiovasvular, #rare and #metabolic diseases. 👉bit.ly/47xG8uh

Nephrologists provide vital cardiorenal protection to #CKD patients, while primary care physicians play a key role in early CKD detection. The common goal: Better #patient outcomes. Curious about this collaboration in CKD care? Watch👉bit.ly/3sv6LBj #nephwitter

23/ Back to your patient 😷: Remember, Mr P has hypertension, #CVD and #T2D. His #lipids are: total cholesterol, 4.2 mmol/L; HDL-C, 1 mmol/L; LDL-C, 1.8 mmol/L; TGs 2.1, mmol/L. He is being treated with BP-regulating therapies, metformin 1 g BID and atorvastatin 80 mg OD.

22/ #Omega3 fatty acids have several proposed beneficial mechanisms of action. #T2D #lipid #CVD 🔓vpjournal.net/article/view/2… 🔓ESC dyslipidaemia guideline: pubmed.ncbi.nlm.nih.gov/3150… 🔓ACC/AHA cholesterol guideline: pubmed.ncbi.nlm.nih.gov/3058…

20/ Icosapent ethyl significantly reduced the risk of CV outcomes in the REDUCE-IT study and is indicated to reduce the risk of CV events in statin-treated patients at high CV risk with elevated TGs. #T2D #lipid #CVD #omega3

18/ #Omega3 fatty acids have been studied in several #CVD prevention trials that included people with #T2D #lipid

17/ #Fibrates reduce TG levels but their impact on #CV outcomes is less clear. The PROMINENT study of pemafibrate was stopped early due to failure to meet the primary endpoint. 🔓PROMINENT study: pubmed.ncbi.nlm.nih.gov/3634… #T2D #lipid #CVD

16/ High TG levels are associated with increased #CV risk. 🔓pubmed.ncbi.nlm.nih.gov/2689… For more information: science-collected.com/educat… #T2D #lipid #CVD

15/ Hypertriglyceridaemia is common in people with #T2D and impacts #lipid metabolism. Several therapies have been used to treat #hypertriglyceridaemia and/or low #HDL-C levels, including #fibrates and #omega-3 fatty acids. #CVD

13/ Let’s take another look at Mr P 😷: He has hypertension, #CVD and #T2D. His #lipids are: total cholesterol, 4.2 mmol/L; HDL-C, 1 mmol/L; LDL-C, 1.8 mmol/L; TGs, 2.1 mmol/L. He is being treated with BP-regulating therapies, metformin 1 g BID and atorvastatin 80 mg OD.

12/ #CV risk is higher in men with #diabetes vs men without diabetes. Additionally, higher total #cholesterol levels are associated with increased risk of #CV death in men with diabetes vs men without diabetes. 🔓MRFIT study: pubmed.ncbi.nlm.nih.gov/8432… #T2D #lipid #CVD